Shanghai Shen Lian Biomedical Corp (688098) — Net Asset Quality Index
Shanghai Shen Lian Biomedical Corp (688098) has a Net Asset Quality Index of 91.3% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.53 Billion minus total liabilities of CN¥133.33 Million yields net assets of CN¥1.40 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check how resilient are Shanghai Shen Lian Biomedical Corp's assets to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shanghai Shen Lian Biomedical Corp Net Asset Quality Index Over Time (2013–2025)
This chart shows how Shanghai Shen Lian Biomedical Corp's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 91.3%, representing net assets of CN¥1.40 Billion against total assets of CN¥1.53 Billion CNY. See working capital to net assets of Shanghai Shen Lian Biomedical Corp to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Shanghai Shen Lian Biomedical Corp (2013–2025)
The table below presents the year-by-year Net Asset Quality Index for Shanghai Shen Lian Biomedical Corp from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Shanghai Shen Lian Biomedical Corp market cap and net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 90.7% | CN¥1.40 Billion | CN¥1.54 Billion | CN¥143.41 Million | ▼ -1.0 pp |
| 2024 | 91.7% | CN¥1.43 Billion | CN¥1.55 Billion | CN¥128.50 Million | ▼ -2.8 pp |
| 2023 | 94.5% | CN¥1.51 Billion | CN¥1.59 Billion | CN¥86.93 Million | ▲ +1.3 pp |
| 2022 | 93.3% | CN¥1.50 Billion | CN¥1.61 Billion | CN¥108.21 Million | ▲ +1.1 pp |
| 2021 | 92.2% | CN¥1.47 Billion | CN¥1.60 Billion | CN¥125.48 Million | ▼ 0.0 pp |
| 2020 | 92.2% | CN¥1.40 Billion | CN¥1.51 Billion | CN¥118.20 Million | ▲ +3.7 pp |
| 2019 | 88.5% | CN¥1.28 Billion | CN¥1.45 Billion | CN¥166.33 Million | ▲ +6.4 pp |
| 2018 | 82.1% | CN¥831.94 Million | CN¥1.01 Billion | CN¥181.18 Million | ▲ +2.8 pp |
| 2017 | 79.4% | CN¥549.27 Million | CN¥692.19 Million | CN¥142.92 Million | ▲ +2.8 pp |
| 2016 | 76.6% | CN¥465.47 Million | CN¥607.79 Million | CN¥142.32 Million | ▲ +11.8 pp |
| 2015 | 64.7% | CN¥317.41 Million | CN¥490.32 Million | CN¥172.90 Million | ▲ +19.1 pp |
| 2014 | 45.7% | CN¥241.57 Million | CN¥528.89 Million | CN¥287.32 Million | ▼ -16.0 pp |
| 2013 | 61.6% | CN¥327.59 Million | CN¥531.53 Million | CN¥203.94 Million | — |